ABSTRACT Metastatic melanoma is challenging to manage. Although targeted- and immune therapies have extended survival, most patients experience therapy resistance. The adaptability of

melanoma cells in nutrient- and therapeutically-challenged environments distinguishes melanoma as an ideal model for investigating therapy resistance. In this review, we discuss the current

available repertoire of melanoma models including two- and three-dimensional tissue cultures, organoids, genetically engineered mice and patient-derived xenograft. In particular, we

highlight how each system recapitulates different features of melanoma adaptability and can be used to better understand melanoma development, progression and therapy resistance. SIMILAR

constitutes ~5% of all skin cancers, it accounts for >75% of skin cancer deaths. The 5-year relative survival rate of patients with localized or regional disease is 98% and 64%,

respectively. In contrast, the 5-year survival rate drops to 23% in patients with metastatic (stage IV) melanoma. One of the most common complications experienced by stage IV melanoma

patients is metastasis to the brain1,2, which is diagnosed in >60% of cases and is identified in up to 80% of patients at autopsy3. Melanoma manifests from the malignant transformation of

melanocytes, cells derived from neural crest stem cells (NCSCs) that produce melanin in the skin4. The NCSC origin of melanocytes underlies the ability of melanoma cells to both migrate to

and thrive in the brain and other major organs, including lungs. There are several types of melanoma that fall into one of three categories: (1) cutaneous melanoma, (2) mucosal melanoma, or

(3) ocular melanoma. Cutaneous melanoma (hereafter melanoma) is the most prevalent type and will be the focus of this review. Four major genetically defined subgroups stratify the patient

population into those whose melanoma possess (1) activating _BRAF_V600 mutations (~50% of patients)5, (2) _NRAS_ mutations (15–20% of patients)6, (3) those with inactivating mutations of

_NF-1_ (~10%, mutually exclusive with _BRAF_), and (4) those with wild-type _BRAF_, wild-type _NRAS_ and wild-type _cKit_ (30–35% of patients)7. Metastatic melanoma was historically viewed

as an untreatable disease until the revolutionary FDA approvals in 2011 and 2014 of targeted- and immune-based therapeutic strategies with notable activity. For patients with _BRAF_V600E/K

mutant melanoma, significant efficacy has been observed with the combination of a BRAF inhibitor and a MEK inhibitor, with a response rate of ~76%8. Despite this remarkable activity, >80%

of patients relapse on the BRAF/MEK inhibitor cocktail, leaving them eligible only for immunotherapy with anti-PD-1 and anti-CTLA4 blockade strategies9. Patients with wild-type _BRAF_ (~35%

of patients) do not have targeted therapy strategies that display significant clinical efficacy10. However, combination MEK inhibition and CDK4/6 inhibition has shown activity

pre-clinically in the _BRAF_ wild-type setting, and clinical testing of this approach is under way. The activity of combination checkpoint inhibitor therapy using anti-PD-1 and anti-CTLA-4

antibodies has demonstrated long-lasting responses in a subset of patients and represents a therapeutic strategy suitable for all genotypes11. However, 60–70% of melanoma patients do not

respond to checkpoint inhibitor therapy due to toxicity, intrinsic resistance, and other reasons not completely understood, leaving surgery, radiation, chemotherapy, and clinical trials to

combat the persisting melanoma cells that do not respond to current standard-of-care strategies12. This is the clinical predicament in 2020 for most patients with metastatic melanoma and

represents the challenge clinicians and investigators are attempting to overcome: therapeutic plateau followed by relapse and mortality. Once disseminated, there are only a few melanoma

patients who experience long-lasting cures from current targeted- and immune therapies. Our evolving understanding of the genetic and non-genetic mechanisms driving melanoma dissemination,

therapy resistance and mortality reveals phenotypic plasticity, inter- and intra-tumoural heterogeneity, and the microbiome among the key drivers13. The dynamic interactions of melanoma

cells with other cellular and acellular constituents of the tumor microenvironment (TME) provide additional mechanisms of homeostatic regulation critical to therapy efficacy14. Recent

technological advancements have only now allowed for characterization of melanoma plasticity and heterogeneity; however, the role served in therapy resistance remains poorly understood15.

Single-cell RNA sequencing approaches have begun to dissect the multicellular ecosystems that are functional in the TME, which comprise immune and non-immune compartments each with secretory

and adhesion signaling landscapes that complicate targeting of melanoma cells. A nuanced observation moving to the forefront of the field is the reality that subpopulations of melanoma

adopt distinct cellular identities akin to NCSCs and stromal cells heterogeneously, within different regions of the same tumor16. These alternative cellular states can be adopted transiently

or permanently, each with implications on sensitivity to a given therapy strategy. Recent reports have characterized therapy-resistant “jackpot” melanoma cells marked by high EGFR and NGFR

expression that pre-exist before therapy and drive therapeutic relapse17. Functional in vitro and in vivo preclinical models of melanoma initially demonstrated the utility of small molecule

BRAF inhibitors for the treatment of _BRAF_-mutant melanoma, providing the scientific rationale for BRAF inhibitor clinical trials18,19. These studies leveraged “traditional” melanoma cell

lines established from patients and cultured on plastic. Critical for the development of future strategies that can overcome the current clinical plateau with targeted- and immune-based

therapeutic strategies, the melanoma field in itself will be a model of melanoma that better recapitulates the multifarious mechanisms that drive resistance in vivo in human patients. Here,

we will discuss distinctive features of melanoma, survey the major model systems leveraged in the study of therapy resistance and comment on prospective directions that may facilitate

discovery of more curative therapeutic modalities. A summary of all available melanoma models is reported in Box 1. BOX 1 MODELLING MELANOMA IN VITRO AND IN VIVO Traditional 2D cell culture

and 3D organoid approaches that incorporate microenvironmental elements allow for investigations of melanoma proliferation following various environmental and therapuetic conditions.

Spheroid, skin reconstruct, and endothelial _trans_-membrane models enable in vitro study of migration, invasive, and metastatic dynamics. The limitations of the above models rests on their

ex vivo nature. Tail vein injection and spontaneous metastasis models are in vivo approaches that allow inspection of micro- and macrometastases in target organs (i.e., lungs, liver).

Sphere, organoid, PDX, and xenograft models of melanoma allow for delineation of cellular heterogeneity and plasticity of melanoma cells that only recently can be unbiasedly characterized by

scRNAseq and barcoding approaches, however, limitations lie in the absence of an immune system. Co-culture approaches incorporating stromal, endothelial, and immune cell types help overcome

this limitation. GEMM, immune- humanized, and autologous adoptive T-cell models currently represent the best approaches to investigate immune dynamics in response to therapy. Limitations

for the GEMM and immune-humanized models lie in the lack of human cells and an autologous immune system, respectively. The isolation and expansion of tumor infiltrating leukocytes along with

tumor from the same patient tumor material for autologous models is a challenging accomplishment. STRIKING FEATURES OF MELANOMA CELLS HIGH GENETIC INSTABILITY Melanoma incidence and

manifestation are correlated with skin-type and ultraviolet radiation (UVR) exposure20. Allelic variation of the melanocortin 1 receptor (MC1R) is causally associated with individuals with

red hair and fair skin due to a switch from eumelanin to phaeomelanin production21,22. Eumelanin is UV-absorbent, whereas pheomelanin is photo-unstable, which is posited to underlie the

increased susceptibility to develop melanoma in individuals with MC1R variants due to the reduced UVR protection and increased reactive oxygen species activity in their skin23. Notably,

melanomas carry the highest mutational load across human tumors as seen by cancer genome deep sequencing, at least in part, due to UVR-induced damage24 (Fig. 1a). Of these mutations, ~80%

display canonical UV signatures (i.e., G > T or C > T transitions that are induced by UVA and UVB, respectively)7. UVA and UVB have been linked to serve a causal role in passenger

mutations as well as ~46% of authenticated driver mutations. Likely, the large number of passenger mutations in melanoma may take potential driver roles under varying environmental or

therapeutic contexts to maintain melanoma cell viability. Key mechanisms of acquired resistance to combination BRAF inhibitor and MEK inhibitor therapy include mutations in _MEK_ and

_NRAS_25; however, it is unknown whether cells expressing these mutations are pre-existing in the tumor or the mutations occur de novo. The high genetic instability of melanoma cells can be

potentially exploited by targeting DNA damage repair proteins (i.e., PARP) to increase the efficacy of targeted therapy26. To better model the high genetic instability of melanoma cells in

mice with intact immune systems (will be discussed further later), investigators have developed genetically engineered mouse melanoma (GEMM) cell lines that have been irradiated to account

for this feature (Fig. 2). PATHWAY PLASTICITY Hardwired into melanoma cells is an incredibly plastic network of signal transduction pathways capable of reactivating and diverting activity

from one pathway to another, allowing survival signals to be continuously transmitted in the context of targeted therapy27 (Fig. 1b). In the case of _BRAF_V600 mutant melanoma cells treated

with BRAF inhibitor, the MAPK pathway is reactivated within hours in vitro and weeks in patients28. Although combination therapy with a BRAF inhibitor and MEK inhibitor delays MAPK pathway

reactivation, it eventually occurs in the majority of cases, as well as hyperactivation of the parallel PI3K axis29,30. Hyperactivation of PI3K signaling in response to MAPK pathway

inhibition can occur through release of negative feedback regulation of ERK phosphorylation on EGFR (i.e., at Thr669)31, as well as kinome reprogramming in response to release of feedback of

ERK upon c-Myc (i.e., at Ser62)32. In _NRAS_ mutant melanoma cells, a robust reactivation of the MAPK pathway also occurs within hours in response to MEK inhibition due to loss of negative

feedback on CRAF33. In this context, concurrently targeting MEK and ERK, or silencing CRAF can overcome MEK inhibitor resistance. Pathway reactivation also occurs in the context of

inhibitors of PI3K/AKT/mTOR, due to loss of negative feedback (i.e., through degradation of IRS-1)34,35,36. Pathway plasticity abrogates the clinical efficacy of targeted agents and warrants

further investigation to identify synthetic lethality approaches that can overcome escape mechanisms. Unfortunately, current attempts to pharmacologically address pathway switching often

involves therapeutic cocktails that are toxic to patients. To model the high pathway plasticity melanoma cells display in response to targeted therapies, investigators can leverage 2D and 3D

approaches to capture signaling kinetics following short-term (minutes to hours following treatment), long-term (days of treatment), and chronic (weeks to months) drug exposure times by

western blotting and reverse-phase protein arrays (RPPAs). Advances in intravital imaging and multiplex in situ approaches coupled with reporters of the MAPK pathway and cell cycle also

allow modeling of melanoma pathway plasticity in vivo37,38. Any therapuetic strategies developed against this feature of melanoma using in vitro models should be validated in patient-derived

xenograft (PDX) and xenograft models before translation into humans (Fig. 2). DEDIFFERENTIATION Metastatic melanoma cells display the striking ability to dedifferentiate to a variety of

states under cellular stress, which drives therapy resistance and mortality16 (Fig. 1c). Murine implantation experiments demonstrated the intrinsically high self-renewal capacity of melanoma

cells, with just one cell capable of reconstituting a heterogenous tumor in mice, a property unique among cancers whereby hundreds to thousands of cells typically need to be implanted to

form a palpable tumor39. As melanocytes derive from NCSCs4, multiple laboratories have identified subsets of melanoma cells that appear to dedifferentiate and display stem-like features akin

to their NCSC precursors16. These stem-like subpopulations display NCSC molecular features (i.e., KDM5B16, CD13340,41,42, CD2043,44, NGFR17,45,46,47, and AQP1) and biological properties

(high plasticity, migratory capacity, and invasiveness) as well as a general loss of pigmentation. The ability of melanoma cells to access developmental programs bestows their remarkable

adaptability to survive in a variety of hostile environments, including systemic circulation48, new organ sites of metastases14, and ex vivo in tissue culture. To model the lineage

plasticity of melanoma cells as they adopt a range of differentiated and dedifferentiated cellular states, investigators can leverage scRNAseq and single-cell RNA FISH approaches to acquire

the multimarker resolution necessary to define and identify these subpopulations of melanoma cells within a given bulk tumor in vivo or a population of cells growing in a culture vessel in

vitro. Investigators should determine whether vulnerabilities of these subpopulations that may present themselves through transcriptomic characterization can be validated in secondary

experiments. To translate clinically, findings must optimally be mirrored in patient-derived tumor tissue and investigators should attempt to identify FDA-approved compounds that can be

repurposed quickly for patient benefit. STROMAL MIMICRY Melanoma cells undergo stromal mimicry, meaning they possess the ability to secrete growth factors and cytokines normally derived from

stromal fibroblasts49,50, monocytes51, macrophages, and neutrophils52, which promote melanoma cell viability in an autocrine loop (Fig. 1d). In addition, melanoma cells secrete a wide

variety of cytokines and growth factors that also influence the tumor microenvironment in a paracrine manner53,54. One mechanism whereby melanoma cells achieve this commensalism-type

relationship with the tumor microenvironment is through the secretion of TGF-β. Secreted TGF-β activates adjacent fibroblasts, which leads to microenvironment reprogramming associated with

an increase in stromal-derived pro-tumorigenic factors (i.e., VEGF, PDGF)55 (Fig. 1e). Aggressive melanoma cells can also form primitive, fluid-conducting vessel-like structures when placed

in three-dimensional matrices56,57. The in vivo biological implications of this phenotype are unclear; however, it provides another powerful example of the ability of subpopulations of

melanoma to dedifferentiate to a state similar to fetal cells as survival in systemic circulation and metastatic dissemination is favored for (Fig. 1f). Melanoma cells display a variety of

immune cell properties. They possess the ability to secrete factors that negatively modulate the immune system (i.e., VEGF, IDO)58. Melanoma cells undergo monocyte-like phagocytosis of

apoptotic cells to fuel metabolic activity59. Melanoma cells express major histocompatibility complex (MHC) class II molecules that allow for functional antigen presentation60,61.

Functionally, melanoma cells operate as a primitive organ. But in contrast to a normal organ where a homeostatic balance exists between the different cell types, melanoma cells dominate the

other cell types and reprogram them in favor of pro-tumorigenic functions. Critical to effectively study and develop therapeutic strategies that completely eliminate melanoma cells from a

patient will be the ability of experimental models to recapitulate the spatial and environmental pressures faced by melanoma cells in the human patient. To model stromal mimicry of melanoma,

investigators can leverage co-culture 2D and 3D in vitro approaches to characterize dynamic interactions between melanoma cells and cells of the tumor microenvironment in the context of

therapy and other stressful conditions (i.e., hypoxia)62 (Fig. 2). Window-chamber approaches can allow validation in vivo of strategies that overcome microenvironment-mediated-resistance

mechanisms. Investigators should determine whether strategies that ablate the stromal features of melanoma cells can prevent metastases and the onset of resistance in a series of PDX and/or

xenograft studies before translation into human patients. TWO-DIMENSIONAL (2D) MELANOMA CELL CULTURE MODELS Though in vitro 2D models are considered as “simple” relative to three-dimensional

(3D) and in vivo models, all existing FDA-approved targeted-based therapies for melanoma began their journey to the clinic as classical 2D adherent cell culture models in the laboratory. In

2D models, melanoma cells are typically grown on tissue culture plates with relatively high levels of oxygen and nutrients63. Although exceptions exist, drugs that have little effect on the

viability of melanoma cells grown in these conditions often do not have efficacy in more realistic 3D in vitro and in vivo models (as discussed later). Therefore, this approach has great

utility in initial high-throughput screens to identify potential hits worth additional investigation. The translational nature of 2D in vitro melanoma models is attributed to the high level

of recapitulation that human normal melanocytes, pre-malignant nevus cells, and primary and metastatic melanoma cells reflect in culture, dependent upon the clinical stage they are derived

from (Fig. 1g). Cultured melanocytes and nevus cells undergo replicative senescence, whereas melanoma cells from invasive primary and metastatic lesions grow as permanent cultures (in part

due to p16 loss)64. Further, melanoma cells, but not melanocytes and nevus cells, form tumors in immune-deficient mice as the prime indicator of their malignant phenotype. Conventional 2D

culture allows for a variety of phenotypes and striking features of melanoma to be interrogated, including cytotoxicity, proliferation (MTT, BRdU), mobility (scratch assay)65, invasiveness

(Boyden chamber), adaptability to hypoxic microenvironments66, protein expression and pathway plasticity (Western blot, reverse-phase protein array) (Fig. 1b), drug sensitivity studies

(high-throughput screening)67, drug durability (colony formation assay), molecular characterization (proteomics), and genomic/genetic characterization (RNA sequencing, whole-exome

sequencing)68 (Fig. 2a). 2D culture also allows for the study of lineage plasticity, with key findings identifying markers of distinct melanoma lineages (Fig. 1c). Of additional benefit,

monocultures are free from contaminating cells, which allows for a clear understanding of what is occurring specifically within melanoma cells relative to other cell types in the tumor

microenvironment in response to a given insult, which can be accomplished through co-culture using transwell plates (Fig. 1e). A total of >2000 melanoma cell lines have been generated by

the field, making this malignancy one of the most extensively studied in cancer. The extensive genetic and genomic analyses performed for most of these melanoma cell lines in systematic

cancer cell-line screens as well as high-throughput drug screens have provided comprehensive information on the underlying genes and pathways responsible for driving melanoma progression and

therapy escape68. Although meaningful insights can be gained from 2D culture, drawbacks to this approach include lack of heterogeneity and the existence of phenotypes that are observed on

plastic that do not reflect melanoma behavior in vivo, and vice versa. For example, melanoma cells proliferate much more rapidly in vitro relative to in vivo rates, likely due to high serum

concentrations and stiffness of support (i.e., plastic). Genetic drift also occurs in long-term passaged cells which can lead to high variability and reduced reproducibility of the results,

due to adaptations to the non-physiological conditions (i.e., oxygen and nutrient levels) in traditional 2D cell culture66. Short-term cultures may overcome some of these issues, but 3D

models that incorporate matrices that better recapitulate in vivo microenvironment architecture may also facilitate the translatability of preclinical findings to the clinic. 3D MELANOMA

CELL CULTURE MODELS 3D SKIN RECONSTRUCT To develop curative therapeutic strategies against melanoma, experimental models unique to melanoma are needed that faithfully recapitulate the in

vivo human disease system. Of the available in vitro melanoma models that exist, the 3D skin reconstruct provides investigators with a contextually representative model69,70. Human skin

consists of (for simplicity) an epidermis and dermis. In the epidermis are located keratinocytes and melanocytes, whereas in the dermis are located fibroblasts with a basement membrane

separating the epidermis from the dermis71. Mouse skin differs significantly from that of human skin due to deviating cellular architecture and physiology (i.e., mouse melanocytes are

located in hair follicles)72. This limits the use of mouse models to investigate cell–matrix and cell–cell interactions between melanoma cells and other cell types. The 3D skin reconstruct

model is a unique tool for the study of melanoma behavior in human skin. The 3D skin reconstruct consists of an “epidermis” containing stratified, differentiated keratinocytes, a functional

basement membrane, and a “dermis” containing fibroblasts embedded in the most prevalent extracellular matrix (ECM) found in the human skin, collagen I70. When melanocytes grow in the 3D skin

reconstruct, they display physiological features of melanocyte homeostasis and melanoma progression observed in the skin of human patients. When incorporating melanoma cells into the 3D

skin reconstruct, they exhibit characteristics analogous to the aggressiveness in the human melanoma patient. Critical to the success of this model is the ability to viably culture

melanocytes, melanoma cells, keratinocytes, and fibroblasts for use in the 3D skin reconstruct. Melanocytes can be derived from human skin, but can also come from embryonic stem cells

(ESCs)73 or induced pluripotent stem (iPS) cells74. The unique architecture and composition of the 3D skin reconstruct allows for careful investigations into autocrine and paracrine loops

between melanoma cells, keratinocytes, and fibroblasts, as well as physical cell–cell contact and tensile forces of ECM fibers75. 3D immune skin reconstruct models have also been developed,

which contain melanoma cells, autologous T cells, and fibroblasts that can be allogeneic76. This approach allows visualization and quantitation of T-cell-mediated tumor cell killing. For

preparation, human fibroblasts are suspended in collagen. Melanoma cells are then layered onto the collagen/fibroblast matrix and allowed to grow overnight (layer 2). They are then covered

with a cell-free collagen layer, and then an equal number of immune T cells (antitumor reactive cytotoxic T cells) are mixed with fibroblasts in collagen and layered on top (layer 4). Four

to 9 days after the addition of T cells, the reconstructs are fixed with formalin and processed for histological evaluation70. The assay can also be used with NK cells instead of T cells or

one can use the total peripheral blood mononuclear cell population. A major advantage of 3D immune assays is the “natural” setting, in which malignant, stromal, and immune cells migrate

toward each other through layers of collagen. Chemoattraction and effective T cell-mediated tumor cell killing can be assessed simultaneously. Their disadvantage is the need for autologous

pairs of T cells and tumor cells, which can be readily produced for melanoma but are more challenging for epithelial tumors. SPHEROIDS In addition to the 3D skin reconstruct, there are other

3D models that capture the heterogeneity and complex intracellular interactions of a tumor similar to the in vivo conditions in human melanoma patients. Spheroids are aggregates of cells

that are embedded in collagen type I, to which the outer cells adhere and invade into. From a biologically early stage, melanoma cells form spheroids but do not invade much into collagen,

displaying a radial growth phase phenotype. In contrast, cells from metastatic lesions are highly invasive (vertical growth phase phenotype) and can be used to assess therapy responses to

signaling inhibitors. Spheroids generally have a hypoxic core and the relative percentage of cells within the core that are dividing or undergoing apoptosis varies among different

melanomas77. The highest viability and proliferative activity of the malignant cells are generally found at the periphery, but the collagen-invading cells in the “dendrites” of a spheroid

undergo a phenotype switch to a more invasive, less proliferative state. When fibroblasts and melanoma cells are co-embedded in collagen, the fibroblasts typically infiltrate into the

spheroids. Overall, spheroids reflect the general conditions in a solid tumor with matrix deposition, heterogeneous growth states, and presence of cancer stem-like cells78.

Semi-high-throughput screens in 384-well plates can automatically evaluate viability and invasion79,80. Thus, spheroid culture represents a valuable cellular condition that is complementary

to conventional 2D culture conditions, reflects a solid tumor in vivo, and should therefore serve as a tool to identify treatment strategies worth investigating in vivo. Limitations of the

spheroid approach include being comprised cells grown in 2D culture, inability to propagate additional spheroids for longitudinal studies, and limited number of cell types that can be

concurrently co-cultured. ORGANOIDS Organoids represent an ex vivo 3D model capable of self-propagating that, in addition to the similar architecture of spheroids, incorporates autologous

lymphoid, myeloid, and other host cell populations that are retained in human tumor isolates. The presence of the different cell lineages allows for powerful investigation into how therapy

may impact the immune compartment to stimulate a greater antitumor response. A recent report leveraging this organoid platform demonstrated that TBK1/IKKε inhibition increased the efficacy

of PD-1 blockade and strongly correlated with in vivo tumor response81. Organoids also allow a high-throughput 384-well format to test the efficacy of single-agent and combinatorial

therapeutic strategies. Spheroids are more “user” friendly compatible with most established cell lines. In contrast, organoid cultures initially require careful establishment before routine

use. However, the organoid approach provides the strength of using cellular material that has not been adapted to culture on plastic, and therefore will better recapitulate melanoma in human

patients. The limitations of organoids lie in the fact that a relatively small number of cells are sampled for their formation, which may have implications on their level of clonality and

heterogeneity they can maintain relative to the clonality and heterogeneity within the original patient tumor population. One can begin to overcome this limitation and increase the

translational potential of this model by establishing organoid cultures from material derived from multiple areas of the same tumor and/or other metastatic sites to better capture the

clonality and heterogeneity that existed with a given patient’s tumor. CAPILLARY NETWORK FORMATION To recapitulate in vivo vasculature dynamics and molecular mechanisms that confer the

ability to survive in systemic circulation (Fig. 1f), the capillary network formation model begins when adherent endothelial cells are first covered with collagen type-1 followed by a second

layer of collagen mixed with fibroblasts. As the fibroblasts begin to constrict the collagen, they attract the endothelial cells, which penetrate the first collagen layer to migrate toward

the fibroblasts82,83. As soon as the endothelial cells establish contact with the fibroblasts, they form round structures, which develop by day 5 into capillary networks. When melanoma cells

are co-embedded with the fibroblasts into the upper collagen layer, they may stimulate or inhibit network formation, which depends on the growth factors and matrix proteins released by the

malignant cells, and differs between cell lines. This assay, while requiring longer incubation times, appears more robust than the Matrigel endothelial network assay, in which endothelial

cells are embedded in the matrix for just a few hours precluding any functional vessel formation84. The capillary network formation model allows for the investigation of pro-angiogenic

mechanisms leveraged by melanoma cells to survive in environmentally stressful conditions, which may facilitate the development of therapuetic modalities that ablate

microenvironment-dependent resistance mechanisms and prevent the ability of melanoma cells to enter vessels to metastasize. The limitations of this approach lie in the lack of functional

vessel formation, which may hinder intra- and extravasation characterization. As with all of the above in vitro models, any potential therapuetic strategies that can ablate the ability of

melanoma cells to hijack angiogenic programs to facilitate metastatic dissemination and therapy escape should be validated in a series of PDX and xenograft models in order for potential

translation into human patients. MURINE IN VIVO MELANOMA MODELS GENETICALLY ENGINEERED MOUSE AND ALLOGRAFT MODELS OF MELANOMA Genetically engineered mouse models (GEMMs) that enable the

spontaneous formation of melanoma have allowed for key insight into melanomagenesis (Fig. 2b). Many of the early GEMMs were modeled on the knowledge of melanocyte developmental biology,

environmental melanoma causative factors and frequently mutated melanoma driver genes (i.e., _BRAF, CDKN2A, CDK4, GNAQ, NRAS_)85. Ultraviolet (UV) radiation is the main environmental risk

factor for melanoma, which underlies its substantial use in investigations of the underlying biology for melanomagenesis. Another strategy to identify pathways involved in the initiation of

melanoma is via the use of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA)), which can be correlated to human etiology of melanoma86. To target melanocytes specifically for

transformation, tissue-specific genes including _Tyr_ and _MITF_ were leveraged86. Incorporation of UV light and/or DMBA could accelerate melanoma development in different GEMM models and

increase their immunogenicity for use in studies of immunotherapies87,88. The _CDKN2A_ genes encodes two overlapping tumor suppressors (_p16INK4A_ and _p14ARF_), which could be targeted by

SV40 T-antigen expression using the melanocyte-specific Tyr promoter. However, loss of _CDKN2A_ alone does not robustly generate cutaneous melanoma. Transgenic mice were generated by

overexpressing the HGF-cMET signaling axis under the control of the murine _MT1_ gene promoter, which constitutively activates the RAS/RAF/MEK/ERK signal transduction pathway. Tyr-Cre

approaches targeting _NRAS_ or _BRAF_ genes also successfully generate cutaneous melanomas after concurrent deletion of tumor suppressor genes _Ink4a/Arf_ or _Pten_. The TCGA reveals the

distinct heterogeneity and high mutational burden of melanoma, which raises a limitation as GEMM models may not reflect the mutational burden found in human patient tumors. This caveat of

GEMM models can be improved by including etiological factors that avoid artificial strong driver oncogenes and allow for tumor evolution (i.e., allowing for loss of heterozygosity and

disease progression from early stage). An example of this lies in the ability to express and/or deactivate genes of interest in a time-dependent as well as tissue-specific manner86. This

technology, which most commonly relies on the Cre-recombinase/LoxP system, allows for the generation of elegant mouse models that conditionally knockout and/or overexpress multiple genes in

a controllable fashion. Using this approach, the McMahon and Bosenburg laboratories generated the constitutively activated BrafV600E mutant with simultaneous deletion of PTEN mouse model,

which is conditionally expressed in a 4-OHT-dependent and melanocyte-specific manner89. The use of GEMMs and allograft approaches to study melanoma suffers from the drawbacks mentioned, but

it does allow the study of immune cell and tumor cell interactions/dynamics in immunocompetent mice. NON-MURINE IN VIVO MELANOMA MODELS In addition, melanoma models in other species

including canine and zebrafish also allow for unique opportunities for investigating in vivo immune consequences of therapy and high-throughput in vivo approaches, respectively. Immense

progress has been recently made with the use of zebrafish for melanoma research from the laboratories of Leonard Zon, Richard White, and Elizabeth Patton90,91. A few discoveries from this

aquatic model system include the interaction of p53 and BRAF to produce melanoma, and the elucidation of developmental pathways in neural crest cells that have implications on melanoma

formation. XENOGRAFT MELANOMA MODELS In vivo models of melanoma allow for physiologic components not fully present in existing in vitro models. Traditionally, in vivo melanoma models are

comprised xenografting tumor cell lines, initially established and cultured on plastic, into immunocompromised mice. Once engrafted, human melanoma cells develop dynamic physical and

secretory interactions with murine stroma, lymphatic, and blood vasculature allowing for the study of melanoma dynamics in vivo. Traditionally, preclinical testing of drug efficacy in

xenograft models relies on the impact on tumor growth and/or metastasis to visceral organs (i.e., lungs, liver). Some melanoma cell lines have a high metastatic potential and can form

spontaneous metastases in the lungs following subcutaneous injection. Serial passaging in mice of cell lines capable of metastasizing to the lungs can eventually select for aggressive

subpopulations of melanoma cells with a higher capacity to form spontaneous metastases in the lung, as is the case for the WM1205Lu and WM451Lu cell lines relative to the parental WM793B and

WM164, respectively63. If a cell line of interest has low metastatic potential, cells can be injected into the tail vein or intracardiac to “force” metastasis to the lungs and brain,

respectively. Although metastases at these visceral sites will form, the cells present will not have gone through critical steps in the classical metastatic cascade (i.e., intravasation,

survival in circulation, extravasation) and therefore not recapitulate true metastases in human patients. An additional limitation of the xenograft approach are the artifacts that arise from

passaging melanoma cell lines ex vivo selects for subpopulations that adapt to non-physiological 2D culture condition and do not necessarily reflect those most active in vivo66. The

consequence of this selection is the poor reproducibility observed between the results in the laboratory and therapy outcome in the clinic92. To address this shortcoming, a technique has

been developed whereby tumor pieces are biopsied from patients and xenografted directly into immune-deficient mice, never touching plastic to retain as much of the in vivo characteristics

present when still in the human patient. Patient-derived xenograft (PDX) models have been demonstrated to be superior for tumor biology studies due to the level of heterogeneity maintained

in the in vivo setting93 (Fig. 2b). The heterogeneity of PDX models, in part, may also depend on the number of tumor sources, which can be similar to cell-line based xenograft models. A

recent study compared cell-line-derived xenografts (CDX) to PDX and found significant differences in hypoxia-regulated gene expression, likely attributed to the 2D cell culture adaptions to

non-physiologic levels of oxygen and alter the fitness of cells when reimplanted in vivo66. Limitations to xenograft and PDX models lie in the necessity to utilize mice that are

immunocompromised or immunodeficient. This poses challenges to the investigation of resistance mechanisms to immune checkpoint inhibitors as well as the potential role of the immune system

in efficacy of targeted therapy. To address these shortcomings for preclinical research into antitumor immune responses, laboratories in the melanoma field including our own have developed

approaches to utilize adoptive T-cell therapy with PDX94, as well as immune-humanized mouse tumor models. Studies leveraging autologous immune-humanized mice incorporate adoptive cell

transfer of tumor-infiltrating T cells and tumor cells from the same patient95, which have so far identified continuous presence of interleukin-2 (IL-2) in the antitumor activity of T

cells96. Advantages of such models are the ability to experimentally interrogate in vivo interactions of human tumor cells with human immune cells in immunodeficient mice. Briefly,

functional human immune systems are reconstituted in immunodeficient mice with the use of human CD34+ cord blood cells, or engraftment of human fetal thymus tissue under the renal capsule

and tail-vein injection of fetal liver-derived CD34+ cells97,98. The quality, yield, and limited potential of CD34 + cells to reconstitute physiologically relevant levels of distinct human

immune cell compartments are a major issue when using human cord blood-derived cells, which can be overcome with the use of fetal liver-derived CD34 + cells. In both instances (cord blood-

or fetal liver-derived CD34 + cells), the major human leukocyte antigen (HLA) allele of the CD34 + cell donor must match the major HLA allele of the tumor cells. Our laboratory has

successfully established over 50 batches of immune-humanized mice with either human cord blood-derived CD34 + cells or fetal tissue-derived CD34 + cells. Renal grafting of fetal tissue from

the same donor of CD34 + cells minimizes alloreactivity and graft-versus-host (GVH)-related issues. The immune-humanization with fetal tissue at the moment allows for superior recapitulation

of immune cell and tumor cell interactions in vivo, however the necessity of fetal tissue makes this model difficult to sustain, impossible in certain countries, and unfortunately does not

provide autologous immune-humanized mice with respect to a given tumor. To overcome this hurdle, our laboratory is developing an induced pluripotent stem cell (iPS) model to generate CD34 + 

stem cells to humanize mice. The advantage of the iPS approach is the donor CD34 + cells are fully autologous with the tumor cells as they are both derived from the same individual. Although

not yet fully optimized, we believe this approach will provide the field with a valuable model to finally begin assessing immune dynamics in response to therapy using PDX models that

reflect the heterogeneity and clonal diversity of human melanomas in vivo. CONCLUSIONS AND FUTURE DIRECTIONS The overall goal of the melanoma field is to develop efficacious therapeutic

strategies to cure every melanoma patient. To achieve this, researchers will need improved melanoma models that optimally mimic human melanoma development, heterogeneity, plasticity,

progression, and also possess molecular characteristics unique to each patient. Given the breadth of models available, researchers have a large selection of ever more sophisticated

approaches that facilitate the logical exploration of underlying mechanisms of melanoma metastasis and therapy escape. For example, if a novel gene is identified as governing melanoma

migration in 2D culture models, researchers can further characterize the robustness of this finding in 3D spheroid and organoid cultures to determine whether validation in more complex and

costly mouse models is warranted (Fig. 2). Ultimately, models are not “real”, but rather are simplified representations of specific biological and molecular phenomena found in melanoma cells

within human patients. To best understand a given biological or molecular process, multiple models should be leveraged to differentiate robust findings that may translate to the human

condition from encouraging data that may be due to artifact. Gaining wider attention is the existence of subpopulations of melanoma that are never eliminated by therapy, despite imaging and

pathological analyses concluding complete response. This minimal residual disease drives therapy relapse in patients and represents one area in need of the best melanoma models dove tailed

with the most sophisticated molecular and genetic techniques to unlock vulnerabilities in these distinct subpopulations of melanoma that will allow for their specific elimination (Fig. 

3a–f). Perhaps the use of PDX models of melanoma in autologous immune-humanized mice will be the ideal approach to interrogate immune- and non-immune-dependent mechanisms that allow residual

disease to persist through therapy and eventually drive therapy relapse. Nonetheless, in vitro assays coupled with scRNAseq and barcoding approaches will continue to provide critical

insights into the development of therapy resistance that will guide how the field addresses therapy resistance. Improved models are required capable of maintaining the in vivo physiologic

pressures that allow melanoma cells to exhibit identical behavior as found in human patients. The complex and dynamic interactions between melanoma cells and other cell types in the TME are

currently only studied in vitro through co-culture of 1–2 additional cell types at a time. Advances in bioprinting and generation of artificial organs may allow the development of in vitro

models that possess all of the relevant cell types and 3D architecture to study melanoma biology and therapeutic resistance. A hurdle to the use of GEMM, xenograft, and PDX mouse models is

the cost of largescale use. A potential replacement to these in vivo models may lie in the high-throughput use of organoids for screening that can be validated in vivo for robust hits. The

development of noninvasive approaches, including liquid biopsies, and the investigation of circulating tumor cells to interrogate treatment efficacy in patients can also empower physicians

with the ability to modify treatment regimens in real time to improve patient overall survival. REFERENCES * Schmidberger, H. et al. Long-term survival of patients after ipilimumab and

hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. _Strahlentherapie und Onkol._ 194, 1144–1151 (2018). Article  Google Scholar  * Arheden, A.

et al. Real-world data on PD-1 inhibitor therapy in metastatic melanoma. _Acta Oncologica_ 58, 962–988 (2019). * Fischer, G. M. et al. Molecular profiling reveals unique immune and metabolic

features of melanoma brain metastases. _Cancer Discov._ 9, 628–645 (2019). Article  PubMed  PubMed Central  Google Scholar  * Cramer, S. F. The origin of epidermal melanocytes. Implications

for the histogenesis of nevi and melanomas. _Arch. Pathol. Lab. Med._ 115, 115–119 (1991). CAS  PubMed  Google Scholar  * Chang, D. Z. et al. Clinical significance of BRAF mutations in

metastatic melanoma. _J. Transl. Med._ 2, 46 (2004). Article  PubMed  PubMed Central  CAS  Google Scholar  * Eskandarpour, M. et al. Frequency of UV-inducible NRAS mutations in melanomas of

patients with germline CDKN2A mutations. _J. Natl Cancer Inst._ 95, 790–798 (2003). Article  CAS  PubMed  Google Scholar  * Hodis, E. et al. A landscape of driver mutations in melanoma.

_Cell_ 150, 251–263 (2012). _HIGHLIGHT: THIS ARTICLE WAS THE FIRST TO ILLUMINATE THE GENETIC LANDSCAPES OF BRAF- AND NRAS-DRIVEN MELANOMAS, AS WELL AS IN THOSE WITH KNOWN NRAS/BRAF

MUTATIONS_. Article  CAS  PubMed  PubMed Central  Google Scholar  * Dummer, R. et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus

vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. _Lancet Oncol._ 19, 1315–1327 (2018). Article  CAS  PubMed  Google Scholar  * Schreuer, M. et al.

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical

trial. _Lancet Oncol._ 18, 464–472 (2017). Article  CAS  PubMed  Google Scholar  * Johnpulle, R. A., Johnson, D. B. & Sosman, J. A. Molecular targeted therapy approaches for BRAF

wild-type melanoma. _Curr. Oncol. Rep._ 18, 6 (2016). Article  PubMed  CAS  Google Scholar  * Rogiers, A. et al. Long-term survival, quality of life, and psychosocial outcomes in advanced

melanoma patients treated with immune checkpoint inhibitors. _J. Oncol._ 2019, 5269062 (2019). Article  PubMed  PubMed Central  CAS  Google Scholar  * Jerby-Arnon, L. et al. A cancer cell

program promotes T cell exclusion and resistance to checkpoint blockade. _Cell_ 175, 984–97.e24 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  * Elkrief, A. et al. Antibiotics

are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. _Oncoimmunology_ 8, e1568812 (2019). Article  PubMed  PubMed

Central  Google Scholar  * Kaur, A. et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. _Nature_ 532, 250–254 (2016). _HIGHLIGHT: THIS ARTICLE WAS

THE FIRST TO MODEL MELANOMA CELLS IN AN AGED VERSUS YOUNG TUMOR MICROENVIRONMENT IN THE CONTEXT OF TARGETED THERAPY_. Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  * Bai, X.,

Fisher, D. E. & Flaherty K. T. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNgamma pathways. _Nat. Rev. Clin. Oncol._ 16, 549–562 (2019).

* Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. _Cell_ 141, 583–594 (2010). _HIGHLIGHT: THIS ARTICLE WAS ONE

OF THE FIRST TO DOCUMENT THE PRESENCE OF A SLOW-CYCLING SUBPOPULATION OF NEURAL CREST-LIKE MELANOMA CELLS CRITICAL IN THERAPY ESCAPE, WHICH HAS NOW BECOME AN EMERGING FIELD OF STUDY IN AND

OF ITSELF_. Article  CAS  PubMed  PubMed Central  Google Scholar  * Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. _Nature_

546, 431–435 (2017). _HIGHLIGHT: THIS ARTICLE IDENTIFIED THE PRE-EXISTENCE OF “JACK POT” SUBPOPULATIONS OF MELANOMA CELLS THAT EVENTUALY DRIVE THERAPY RESISTANCE_. Article  ADS  CAS  PubMed

  PubMed Central  Google Scholar  * Sharma, A. et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. _Cancer Res._ 65, 2412–2421 (2005). Article 

CAS  PubMed  Google Scholar  * Liu, J. et al. Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. _Oncogene_ 26, 1954–1958 (2007). Article  CAS 

PubMed  Google Scholar  * Chang, C. et al. More skin, more sun, more tan, more melanoma. _Am. J. Public Health_ 104, e92–e99 (2014). Article  PubMed  PubMed Central  Google Scholar  * Chen,

S. et al. Palmitoylation-dependent activation of MC1R prevents melanomagenesis. _Nature_ 549, 399–403 (2017). Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  * Valverde, P. et al.

The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. _Hum. Mol. Genet._ 5, 1663–1666 (1996). Article  CAS  PubMed  Google Scholar  * Nasti, T. H. &

Timares, L. MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer. _Photochemistry Photobiol._ 91, 188–200 (2015). Article  CAS  Google Scholar  *

Buttner, R. et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. _ESMO Open._ 4, e000442 (2019). Article  PubMed  PubMed Central  Google Scholar  *

Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. _Nature_ 468, 973–977 (2010). Article  ADS  CAS  PubMed  PubMed Central  Google

Scholar  * Possik, P. A. et al. Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. _Cell Rep._ 9,

1375–1386 (2014). Article  CAS  PubMed  Google Scholar  * Smith, L. K., Rao, A. D. & McArthur, G. A. Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.

_Pharmacol. Res._ 107, 42–47 (2016). Article  CAS  PubMed  Google Scholar  * Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be

overcome by cotargeting MEK and IGF-1R/PI3K. _Cancer Cell._ 18, 683–695 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Johannessen, C. M. et al. COT drives resistance to RAF

inhibition through MAP kinase pathway reactivation. _Nature_ 468, 968–972 (2010). Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  * Moriceau, G. et al. Tunable-combinatorial

mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. _Cancer Cell._ 27, 240–256 (2015). Article  CAS  PubMed  PubMed Central 

Google Scholar  * Mirzoeva, O. K. et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK

inhibition. _Cancer Res._ 69, 565–572 (2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK

inhibition in triple-negative breast cancer. _Cell_ 149, 307–321 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Rebecca, V. W. et al. Vertical inhibition of the MAPK pathway

enhances therapeutic responses in NRAS-mutant melanoma. _Pigment Cell Melanoma Res._ 27, 1154–1158 (2014). Article  CAS  PubMed  PubMed Central  Google Scholar  * Zitzmann, K. et al.

Compensatory activation of Akt in response to mTOR and Raf inhibitors—a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. _Cancer Lett._ 295, 100–109 (2010).

Article  CAS  PubMed  Google Scholar  * Wan, X., Harkavy, B., Shen, N., Grohar, P. & Helman, L. J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent

mechanism. _Oncogene_ 26, 1932–1940 (2007). Article  CAS  PubMed  Google Scholar  * Sun, S. Y. et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of

rapamycin inhibition. _Cancer Res._ 65, 7052–7058 (2005). Article  CAS  PubMed  Google Scholar  * Hirata, E. et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant

microenvironments with high integrin beta1/FAK signaling. _Cancer Cell._ 27, 574–588 (2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Teh, J. L. F. et al. In vivo E2F

reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. _Cancer Discov._ 8, 568–581 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar

  * Quintana, E. et al. Efficient tumour formation by single human melanoma cells. _Nature_ 456, 593–598 (2008). Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  * Shidal, C.,

Singh, N. P., Nagarkatti, P. & Nagarkatti, M. MicroRNA-92 expression in CD133 + melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent

activation of TGF-beta. _Cancer Res_. 79, 3622–3635 (2019). * Frank, N. Y. et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. _Cancer Res._ 65,

4320–4333 (2005). Article  CAS  PubMed  Google Scholar  * Klein, W. M. et al. Increased expression of stem cell markers in malignant melanoma. _Mod. Pathol._ 20, 102–107 (2007). Article  CAS

  PubMed  Google Scholar  * Fang, D. et al. A tumorigenic subpopulation with stem cell properties in melanomas. _Cancer Res._ 65, 9328–9337 (2005). Article  CAS  PubMed  Google Scholar  *

Zabierowski, S. E. & Herlyn, M. Melanoma stem cells: the dark seed of melanoma. _J. Clin. Oncol._ 26, 2890–2894 (2008). Article  PubMed  Google Scholar  * Redmer, T. et al. The nerve

growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. _PLoS ONE_ 9, e92596 (2014). Article  ADS  PubMed  PubMed Central  CAS  Google

Scholar  * Fallahi-Sichani, M. et al. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. _Mol. Syst. Biol._ 13,

905 (2017). Article  PubMed  PubMed Central  CAS  Google Scholar  * Mehta, A. et al. Immunotherapy resistance by inflammation-induced dedifferentiation. _Cancer Discov._ 8, 935–943 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar  * Boisvert-Adamo, K., Longmate, W., Abel, E. V. & Aplin, A. E. Mcl-1 is required for melanoma cell resistance to anoikis. _Mol.

Cancer Res._ 7, 549–556 (2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Loffek, S. et al. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in

fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms. _J. Investig. Dermatol._ 124, 638–643 (2005). Article  PubMed  Google Scholar  * Brenner, M.,

Degitz, K., Besch, R. & Berking, C. Differential expression of melanoma-associated growth factors in keratinocytes and fibroblasts by ultraviolet A and ultraviolet B radiation. _Br. J.

Dermatol._ 153, 733–739 (2005). Article  CAS  PubMed  Google Scholar  * Graeven, U. & Herlyn, M. In vitro growth patterns of normal human melanocytes and melanocytes from different

stages of melanoma progression. _J. Immunother._ 12, 199–202 (1992). Article  CAS  PubMed  Google Scholar  * Peng, H. H., Liang, S., Henderson, A. J. & Dong, C. Regulation of

interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. _Exp. Cell Res._ 313, 551–559 (2007). Article  CAS  PubMed  Google Scholar  * Whipple, C. A. &

Brinckerhoff, C. E. BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. _Br. J. Cancer_ 111, 1625–1633 (2014). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Busse, A. & Keilholz, U. Role of TGF-beta in melanoma. _Curr. Pharm. Biotechnol._ 12, 2165–2175 (2011). Article  CAS  PubMed  Google Scholar  *

Lazar-Molnar, E., Hegyesi, H., Toth, S. & Falus, A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. _Cytokine_ 12, 547–554 (2000). Article  CAS  PubMed 

Google Scholar  * Rodewald, A. K. et al. Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis. _J.

Cutaneous Pathol_. 46, 570–578 (2019). * Hendrix, M. J. et al. Tumor cell vascular mimicry: novel targeting opportunity in melanoma. _Pharmacol. Therapeut._ 159, 83–92 (2016). Article  CAS

  Google Scholar  * Lacal, P. M. et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. _J. Investig. Dermatol._ 115, 1000–1007

(2000). Article  CAS  PubMed  Google Scholar  * Lugini, L. et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. _Lab.

Investig._ 83, 1555–1567 (2003). Article  CAS  PubMed  Google Scholar  * Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic

melanoma. _Sci. Transl. Med_. 10, eaar3342 (2018). * Brady, M. S., Eckels, D. D., Ree, S. Y., Schultheiss, K. E. & Lee, J. S. MHC class II-mediated antigen presentation by melanoma

cells. _J. Immunother. Emphas. Tumor Immunol._ 19, 387–397 (1996). Article  CAS  Google Scholar  * Somasundaram, R. et al. Tumor-associated B-cells induce tumor heterogeneity and therapy

resistance. _Nat. Commun._ 8, 607 (2017). Article  ADS  PubMed  PubMed Central  CAS  Google Scholar  * Beaumont, K. A., Mohana-Kumaran, N. & Haass, N. K. _Modeling melanoma in vitro and

in vivo_. in _Healthcare_, Vol. 2. 27–46 (Multidisciplinary Digital Publishing Institute, Basel, 2013). * Sviderskaya, E. V. et al. p16(Ink4a) in melanocyte senescence and differentiation.

_J. Natl Cancer Inst._ 94, 446–454 (2002). Article  CAS  PubMed  Google Scholar  * Satyamoorthy, K., Li, G., Vaidya, B., Kalabis, J. & Herlyn, M. Insulin-like growth factor-I-induced

migration of melanoma cells is mediated by interleukin-8 induction. _Cell Growth Differ.: Mol. Biol. J. Am. Assoc. Cancer Res._ 13, 87–93 (2002). CAS  Google Scholar  * Bhadury, J. et al.

Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. _Oncotarget_ 7, 23801–23811 (2016). Article  PubMed 

PubMed Central  Google Scholar  * Park, E. S. et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. _Mol. Cancer

Therapeut._ 9, 257–267 (2010). Article  CAS  Google Scholar  * Konieczkowski, D. J. et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. _Cancer

Discov._ 4, 816–827 (2014). Article  CAS  PubMed  PubMed Central  Google Scholar  * Ghosh, S. et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a

high density oligonucleotide array study. _J. Cell. Physiol._ 204, 522–531 (2005). Article  ADS  CAS  PubMed  Google Scholar  * Li, L., Fukunaga-Kalabis, M. & Herlyn, M. The

three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. _J. Vis. Exp._ 54, e2937 (2011). * Mancianti, M. L. et al. Growth and phenotypic

characteristics of human nevus cells in culture. _J. Investig. Dermatol._ 90, 134–141 (1988). Article  CAS  PubMed  Google Scholar  * Silver, A. F., Fleischmann, R. D. & Chase, H. B. The

fine structure of the melanocytes of the adult mouse hair follicle during their amelanotic phase (telogen and early anagen). _Am. J. Anat._ 150, 653–658 (1977). Article  CAS  PubMed  Google

Scholar  * Gola, M., Czajkowski, R., Bajek, A., Dura, A. & Drewa, T. Melanocyte stem cells: biology and current aspects. _Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res._ 18, Ra155–Ra159

(2012). Article  CAS  Google Scholar  * Hosaka, C. et al. Induced pluripotent stem cell-derived melanocyte precursor cells undergoing differentiation into melanocytes. _Pigment Cell

Melanoma Res_. 32, 623–-633 (2019). * Murekatete, B. et al. Targeting insulin-like growth factor-i and extracellular matrix interactions in melanoma progression. _Sci. Rep._ 8, 583 (2018).

Article  ADS  PubMed  PubMed Central  CAS  Google Scholar  * Kaur, A. et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility.

_Cancer Discov._ 9, 64–81 (2019). Article  CAS  PubMed  Google Scholar  * Raza, A. et al. Oxygen mapping of melanoma spheroids using small molecule platinum probe and phosphorescence

lifetime imaging microscopy. _Sci. Rep._ 7, 10743 (2017). Article  ADS  PubMed  PubMed Central  CAS  Google Scholar  * Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf

kinase with potent antimelanoma activity. _Proc. Natl Acad. Sci. USA_ 105, 3041–3046 (2008). Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  * Friedrich, J., Seidel, C., Ebner, R.

& Kunz-Schughart, L. A. Spheroid-based drug screen: considerations and practical approach. _Nat. Protoc._ 4, 309–324 (2009). Article  CAS  PubMed  Google Scholar  * Tung, Y. C. et al.

High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. _Analyst_ 136, 473–478 (2011). Article  ADS  CAS  PubMed  Google Scholar  * Jenkins, R. W. et al. Ex vivo

profiling of PD-1 blockade using organotypic tumor spheroids. _Cancer Discov._ 8, 196–215 (2018). Article  CAS  PubMed  Google Scholar  * Noma, K. et al. The essential role of fibroblasts

in esophageal squamous cell carcinoma-induced angiogenesis. _Gastroenterology_ 134, 1981–1993 (2008). Article  PubMed  Google Scholar  * Velazquez, O. C., Snyder, R., Liu, Z. J., Fairman, R.

M. & Herlyn, M. Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. _FASEB J._ 16, 1316–1318 (2002). Article  CAS 

PubMed  Google Scholar  * Khoo, C. P., Micklem, K. & Watt, S. M. A comparison of methods for quantifying angiogenesis in the Matrigel assay in vitro. _Tissue Eng. Part C., Methods_ 17,

895–906 (2011). Article  CAS  Google Scholar  * Neagu, M. et al. Chemically induced skin carcinogenesis: updates in experimental models (Review). _Oncol. Rep._ 35, 2516–2528 (2016). Article

  CAS  PubMed  PubMed Central  Google Scholar  * Perez-Guijarro, E., Day, C. P., Merlino, G. & Zaidi, M. R. Genetically engineered mouse models of melanoma. _Cancer_ 123, 2089–2103

(2017). Article  PubMed  Google Scholar  * Wang, J. et al. UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. _Pigment Cell Melanoma

Res._ 30, 428–435 (2017). _HIGHLIGHT: THIS ARTICLES PROVIDES THE MELANOMA FIELD WITH A TOOL CELL LINE TO INTERROGATE MELANOMA/IMMUNE-DYNAMICS IN VIVO_. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Viros, A. et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. _Nature_ 511, 478–482 (2014). _HIGHLIGHT: THIS ARTICLE PROVIDES

MECHANISTIC INSIGHT INTO HOW UVR ACCELERATES MELANOGENESIS_. Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  * Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce

metastatic melanoma. _Nat. Genet._ 41, 544–552 (2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * White, R. M. et al. Transparent adult zebrafish as a tool for in vivo

transplantation analysis. _Cell Stem Cell_ 2, 183–189 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Patton, E. E. et al. BRAF mutations are sufficient to promote nevi

formation and cooperate with p53 in the genesis of melanoma. _Curr. Biol._ 15, 249–254 (2005). Article  CAS  PubMed  Google Scholar  * Tveit, K. M. & Pihl, A. Do cell lines in vitro

reflect the properties of the tumours of origin? A study of lines derived from human melanoma xenografts. _Br. J. Cancer_ 44, 775–786 (1981). Article  CAS  PubMed  PubMed Central  Google

Scholar  * Harris, A. L., Joseph, R. W. & Copland, J. A. Patient-derived tumor xenograft models for melanoma drug discovery. _Expert Opin. Drug Discov._ 11, 895–906 (2016). Article  CAS

  PubMed  Google Scholar  * Atay, C. et al. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. _Clin. Cancer Res._ 25, 2783–2794 (2019). Article  PubMed  PubMed Central 

Google Scholar  * Einarsdottir, B. O. et al. A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. _Cell

Death Dis._ 9, 810 (2018). Article  PubMed  PubMed Central  CAS  Google Scholar  * Jespersen, H. et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous

immune-humanized mouse model. _Nat. Commun._ 8, 707 (2017). _HIGHLIGHT: THIS ARTICLE DEMONSTRATES HOW INVESTIGATORS CAN INVESTIGATE MELANOMA BIOLOGY IN THE CONTEXT OF AN AUTLOGOUS IMMUNE

SYSTEM IN VIVO_. Article  ADS  PubMed  PubMed Central  CAS  Google Scholar  * Hu, Z., Xia, J., Fan, W., Wargo, J. & Yang, Y. G. Human melanoma immunotherapy using tumor antigen-specific

T cells generated in humanized mice. _Oncotarget_ 7, 6448–6459 (2016). Article  PubMed  PubMed Central  Google Scholar  * Tonomura, N., Habiro, K., Shimizu, A., Sykes, M. & Yang, Y. G.

Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. _Blood_ 111, 4293–4296 (2008). Article  CAS  PubMed  PubMed Central 

Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * The Wistar Institute, Melanoma Research Center, Philadelphia, PA, USA Vito W. Rebecca, Rajasekharan

Somasundaram & Meenhard Herlyn Authors * Vito W. Rebecca View author publications You can also search for this author inPubMed Google Scholar * Rajasekharan Somasundaram View author

publications You can also search for this author inPubMed Google Scholar * Meenhard Herlyn View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING

AUTHOR Correspondence to Meenhard Herlyn. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains

neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons

Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original

author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the

article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use

is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Rebecca, V.W., Somasundaram, R. & Herlyn, M. Pre-clinical modeling of cutaneous

melanoma. _Nat Commun_ 11, 2858 (2020). https://doi.org/10.1038/s41467-020-15546-9 Download citation * Received: 12 January 2017 * Accepted: 16 March 2020 * Published: 05 June 2020 * DOI:

https://doi.org/10.1038/s41467-020-15546-9 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative